These findings, coupled with the availability of sEH positron emission tomography (PET) tracers for in vivo imaging [62], make sEH an attractive therapeutic target for AD, tauopathy diseases, and possibly other neurodegenerative disorders. Here, EPHX2 is linked to Alzheimer disease.